MegaPro Biomedical was invited to “The Third China BioMed Innovation and Investment Conference” hosted by PhIRDA

 Home News MegaPro Biomedical was invited to “The Third China BioMed Innovation and Investment Conference” hosted by PhIRDA

Dr. Jassy Wang will represent MegaPro Biomedical in “The Third China BioMed Innovation and Investment Conference hosted by PhIRDA in Suzhou. In addition to interacting with the key pharmaceutical, new drug, and medical equipment companies as well as investment organizations in China, she will conduct a special roadshow between 4.40pm and 5 pm on September 19, 2018. The theme of the roadshow is “a kind of nanomedicine that can treat iron deficiency anemia and be used as MRI contrast agent” and centers around the successful development of two indications from superparamagnetic iron oxide nanoparticle. The two indications are MPB-1514 iron supplement for iron deficiency anemia and MPB-1523 contrast agent for hepatocellular carcinoma, and both have obtained the approval from the US FDA for Phase II of clinical trials.

About MPB-1514 Iron Supplement for Iron deficiency anemia

MPB-1514 is synthesized with superparamagnetic iron oxide nanoparticle as the core and modified with polyethylene glycol using PEGlyation technology platform. It has highly efficient macrophage phagocytotic property and the modification with non-carbohydrate has been proven to not trigger allergic reaction through animal testing. As a result, high dose MPB-1514 injection can provide sufficient iron for the liver which is responsible for hematopoiesis. This will improve the symptoms of iron deficiency anemia and reduce the number of times patients have to visit the hospital.

About MPB-1523 Contrast Agent for Hepatocellular Carcinoma

MPB-1523 is synthesized with superparamagnetic iron oxide nanoparticle as the core and modified with polyethylene glycol using PEGlyation technology platform. It has high magnetic relaxation and high efficiency for macrophage phagocytosis. These properties can be applied to improve image contrast of organs and tissues rich in reticuloendothelial cells such as liver, spleen and lymph nodes, allowing medical personnel to decide whether the tumor is benign or malignant and whether lymphatic metastasis has occurred. In addition, there is no issue of heavy metal deposit in human brain currently faced by commercial Gd-based contrast agents.

About MegaPro Biomedical

MegaPro Biomedical is a nanomedicine development company that spin-off from ITRI and has nanoparticle and nano-micelle as the core technology. Currently, the nanoparticle product has two indications namely MPB-1514 iron supplement for iron deficiency anemia and MPB-1523 contrast agent for hepatocellular carcinoma that have been approved by the US FDA for Phase II of clinical trials. In addition, the company is also using nano-micelle technology to construct antineoplastic drug platform to accelerate the development of new antineoplastic drug formula. For more information regarding the company, please visit http://www.megaprobio.com